|
1
|
Barbarot S, Auziere S, Gadkari A,
Girolomoni G, Puig L, Simpson EL, Margolis DJ, de Bruin-Weller M
and Eckert L: Epidemiology of atopic dermatitis in adults: Results
from an international survey. Allergy. 73:1284–1293. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Asher MI, Montefort S, Björkstén B, Lai
CK, Strachan DP, Weiland SK and Williams H: ISAAC Phase Three Study
Group: Worldwide time trends in the prevalence of symptoms of
asthma, allergic rhinoconjunctivitis, and eczema in childhood:
ISAAC Phases One and Three repeat multicountry cross-sectional
surveys. Lancet. 368:733–743. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nutten S: Atopic dermatitis: Global
epidemiology and risk factors. Ann Nutr Metab. 66 Suppl 1:8–16.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dharmage SC, Lowe AJ, Matheson MC, Burgess
JA, Allen KJ and Abramson MJ: Atopic dermatitis and the atopic
march revisited. Allergy. 69:17–27. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mortz CG, Andersen KE, Dellgren C,
Barington T and Bindslev-Jensen C: Atopic dermatitis from
adolescence to adulthood in the TOACS cohort: Prevalence,
persistence and comorbidities. Allergy. 70:836–845. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Constantin MM: Value and impact of patch
testing in patients with allergic contact dermatitis. Rom J Lab
Med. 20:101–106. 2012.
|
|
7
|
Montes-Torres A, Llamas-Velasco M,
Pérez-Plaza A, Solano-López G and Sánchez-Pérez J: Biological
Treatments in Atopic Dermatitis. J Clin Med. 4:593–613. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Milgrom H, Fick RB Jr, Su JQ, Reimann JD,
Bush RK, Watrous ML and Metzger WJ: Treatment of allergic asthma
with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J
Med. 341:1966–1973. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Salvi SS and Babu KS: Treatment of
allergic asthma with monoclonal anti-IgE antibody. N Engl J Med.
342:1292–1293. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu KC and Jabbar-Lopez ZK: Omalizumab, an
Anti-IgE mAb, receives approval for the treatment of chronic
idiopathic/spontaneous urticaria. J Invest Dermatol. 135:13–15.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Magerl M, Altrichter S, Borzova E,
Giménez-Arnau A, Grattan CE, Lawlor F, Mathelier-Fusade P, Meshkova
RY, Zuberbier T, Metz M, et al: The definition, diagnostic testing,
and management of chronic inducible urticarias - The EAACI/GA(2)
LEN/EDF/UNEV consensus recommendations 2016 update and revision.
Allergy. 71:780–802. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vashisht P and Casale T: Omalizumab for
treatment of allergic rhinitis. Expert Opin Biol Ther. 13:933–945.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Loizou D, Enav B, Komlodi-Pasztor E, Hider
P, Kim-Chang J, Noonan L, Taber T, Kaushal S, Limgala R, Brown M,
et al: A pilot study of omalizumab in eosinophilic esophagitis.
PLoS One. 10:e01134832015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lieberman JA and Chehade M: Use of
omalizumab in the treatment of food allergy and anaphylaxis. Curr
Allergy Asthma Rep. 13:78–84. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
El-Qutob D: Off-label uses of omalizumab.
Clin Rev Allergy Immunol. 50:84–96. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wright JD, Chu HM, Huang CH, Ma C, Chang
TW and Lim C: Structural and physical basis for anti-IgE therapy.
Sci Rep. 5:115812015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu J, Lester P, Builder S and Shire SJ:
Characterization of complex formation by humanized anti-IgE
monoclonal antibody and monoclonal human IgE. Biochemistry.
34:10474–10482. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brownell J and Casale TB: Anti-IgE
therapy. Immunol Allergy Clin North Am. 24:551–568. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sallmann E, Reininger B, Brandt S, Duschek
N, Hoflehner E, Garner-Spitzer E, Platzer B, Dehlink E, Hammer M,
Holcmann M, et al: High-affinity IgE receptors on dendritic cells
exacerbate Th2-dependent inflammation. J Immunol. 187:164–171.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rissoan MC, Soumelis V, Kadowaki N,
Grouard G, Briere F, de Waal Malefyt R and Liu YJ: Reciprocal
control of T helper cell and dendritic cell differentiation.
Science. 283:1183–1186. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Noga O, Hanf G and Kunkel G: Immunological
and clinical changes in allergic asthmatics following treatment
with omalizumab. Int Arch Allergy Immunol. 131:46–52. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kitaura J, Song J, Tsai M, Asai K,
Maeda-Yamamoto M, Mocsai A, Kawakami Y, Liu FT, Lowell CA, Barisas
BG, et al: Evidence that IgE molecules mediate a spectrum of
effects on mast cell survival and activation via aggregation of the
FcepsilonRI. Proc Natl Acad Sci USA. 100:12911–12916. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Noga O, Hanf G, Brachmann I, Klucken AC,
Kleine-Tebbe J, Rosseau S, Kunkel G, Suttorp N and Seybold J:
Effect of omalizumab treatment on peripheral eosinophil and
T-lymphocyte function in patients with allergic asthma. J Allergy
Clin Immunol. 117:1493–1499. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lane JE, Cheyney JM, Lane TN, Kent DE and
Cohen DJ: Treatment of recalcitrant atopic dermatitis with
omalizumab. J Am Acad Dermatol. 54:68–72. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thaiwat S and Sangasapaviliya A:
Omalizumab treatment in severe adult atopic dermatitis. Asian Pac J
Allergy Immunol. 29:357–360. 2011.PubMed/NCBI
|
|
26
|
Fernández-Antón Martínez MC, Leis-Dosil V,
Alfageme-Roldán F, Paravisini A, Sánchez-Ramón S and Suárez
Fernández R: Omalizumab for the treatment of atopic dermatitis.
Actas Dermosifiliogr. 103:624–628. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Iyengar SR, Hoyte EG, Loza A, Bonaccorso
S, Chiang D, Umetsu DT and Nadeau KC: Immunologic effects of
omalizumab in children with severe refractory atopic dermatitis: A
randomized, placebo-controlled clinical trial. Int Arch Allergy
Immunol. 162:89–93. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Velling P, Skowasch D, Pabst S, Jansen E,
Tuleta I and Grohé C: Improvement of quality of life in patients
with concomitant allergic asthma and atopic dermatitis: One year
follow-up of omalizumab therapy. Eur J Med Res. 16:407–410. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim DH, Park KY, Kim BJ, Kim MN and Mun
SK: Anti-immunoglobulin E in the treatment of refractory atopic
dermatitis. Clin Exp Dermatol. 38:496–500. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Romano C, Sellitto A, De Fanis U,
Balestrieri A, Savoia A, Abbadessa S, Astarita C and Lucivero G:
Omalizumab for difficult-to-treat dermatological conditions:
Clinical and immunological features from a retrospective real-life
experience. Clin Drug Investig. 35:159–168. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vigo PG, Girgis KR, Pfuetze BL, Critchlow
ME, Fisher J and Hussain I: Efficacy of anti-IgE therapy in
patients with atopic dermatitis. J Am Acad Dermatol. 55:168–170.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Heil PM, Maurer D, Klein B, Hultsch T and
Stingl G: Omalizumab therapy in atopic dermatitis: Depletion of IgE
does not improve the clinical course - a randomized,
placebo-controlled and double blind pilot study. J Dtsch Dermatol
Ges. 8:990–998. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Krathen RA and Hsu S: Failure of
omalizumab for treatment of severe adult atopic dermatitis. J Am
Acad Dermatol. 53:338–340. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang HH, Li YC and Huang YC: Efficacy of
omalizumab in patients with atopic dermatitis: A systematic review
and meta-analysis. J Allergy Clin Immunol. 138:1719–1722. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hotze M, Baurecht H, Rodríguez E,
Chapman-Rothe N, Ollert M, Fölster-Holst R, Adamski J, Illig T,
Ring J and Weidinger S: Increased efficacy of omalizumab in atopic
dermatitis patients with wild-type filaggrin status and higher
serum levels of phosphatidylcholines. Allergy. 69:132–135. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Andreae DA and Wang J: Immunologic effects
of omalizumab in children with severe refractory atopic dermatitis:
A randomized, placebo-controlled clinical trial. Pediatrics. 134
Suppl 3:S1602014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shirley M: Dupilumab: First global
approval. Drugs. 77:1115–1121. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hamilton JD, Ungar B and Guttman-Yassky E:
Drug evaluation review: Dupilumab in atopic dermatitis.
Immunotherapy. 7:1043–1058. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vella A, Teague TK, Ihle J, Kappler J and
Marrack P: Interleukin-4 (IL-4) or IL-7 prevents the death of
resting T cells: stat6 is probably not required for the effect of
IL-4. J Exp Med. 186:325–330. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Enelow R, Baramki DF and Borish LC:
Inhibition of effector T lymphocytes mediated through antagonism of
IL-4. J Allergy Clin Immunol. 113:560–562. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Schleimer RP, Sterbinsky SA, Kaiser J,
Bickel CA, Klunk DA, Tomioka K, Newman W, Luscinskas FW, Gimbrone
MA Jr, McIntyre BW, et al: IL-4 induces adherence of human
eosinophils and basophils but not neutrophils to endothelium.
Association with expression of VCAM-1. J Immunol. 148:1086–1092.
1992.PubMed/NCBI
|
|
42
|
Tanaka T, Hitomi Y, Kambayashi Y, Hibino
Y, Fukutomi Y, Shibata A, Sugimoto N, Hatta K, Eboshida A,
Konoshita T, et al: The differences in the involvements of loci of
promoter region and Ile50Val in interleukin-4 receptor A chain gene
between atopic dermatitis and Japanese cedar pollinosis. Allergol
Int. 61:57–63. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hackstein H, Hecker M, Kruse S, Bohnert A,
Ober C, Deichmann KA and Bein G: A novel polymorphism in the 5
promoter region of the human interleukin-4 receptor alpha-chain
gene is associated with decreased soluble interleukin-4 receptor
protein levels. Immunogenetics. 53:264–269. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hershey GK, Friedrich MF, Esswein LA,
Thomas ML and Chatila TA: The association of atopy with a
gain-of-function mutation in the alpha subunit of the interleukin-4
receptor. N Engl J Med. 337:1720–1725. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tamura K, Suzuki M, Arakawa H, Tokuyama K
and Morikawa A: Linkage and association studies of STAT6 gene
polymorphisms and allergic diseases. Int Arch Allergy Immunol.
131:33–38. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Howell MD, Fairchild HR, Kim BE, Bin L,
Boguniewicz M, Redzic JS, Hansen KC and Leung DY: Th2 cytokines act
on S100/A11 to downregulate keratinocyte differentiation. J Invest
Dermatol. 128:2248–2258. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Howell MD, Kim BE, Gao P, Grant AV,
Boguniewicz M, Debenedetto A, Schneider L, Beck LA, Barnes KC and
Leung DY: Cytokine modulation of atopic dermatitis filaggrin skin
expression. J Allergy Clin Immunol. 120:150–155. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kim BE, Leung DY, Boguniewicz M and Howell
MD: Loricrin and involucrin expression is down-regulated by Th2
cytokines through STAT-6. Clin Immunol. 126:332–337. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hsieh FH, Lam BK, Penrose JF, Austen KF
and Boyce JA: T helper cell type 2 cytokines coordinately regulate
immunoglobulin E-dependent cysteinyl leukotriene production by
human cord blood-derived mast cells: Profound induction of
leukotriene C(4) synthase expression by interleukin 4. J Exp Med.
193:123–133. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Beck LA, Thaçi D, Hamilton JD, Graham NM,
Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, et al:
Dupilumab treatment in adults with moderate-to-severe atopic
dermatitis. N Engl J Med. 371:130–139. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hamilton JD, Suárez-Fariñas M, Dhingra N,
Cardinale I, Li X, Kostic A, Ming JE, Radin AR, Krueger JG, Graham
N, et al: Dupilumab improves the molecular signature in skin of
patients with moderate-to-severe atopic dermatitis. J Allergy Clin
Immunol. 134:1293–1300. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Blakely K, Gooderham M and Papp K:
Dupilumab, a monoclonal antibody for atopic dermatitis: A review of
current literature. Skin Therapy Lett. 21:1–5. 2016.PubMed/NCBI
|
|
53
|
Thaçi D, Simpson EL, Beck LA, Bieber T,
Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, et
al: Efficacy and safety of dupilumab in adults with
moderate-to-severe atopic dermatitis inadequately controlled by
topical treatments: A randomised, placebo-controlled, dose-ranging
phase 2b trial. Lancet. 387:40–52. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tsianakas A, Luger TA and Radin A:
Dupilumab treatment improves quality of life in adult patients with
moderate-to-severe atopic dermatitis: Results from a randomized,
placebo-controlled clinical trial. Br J Dermatol. 178:406–414.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Simpson EL, Bieber T, Guttman-Yassky E,
Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y,
Lacour JP, et al: SOLO 1 and SOLO 2 investigators: Two phase 3
trials of dupilumab versus placebo in atopic dermatitis. N Engl J
Med. 375:2335–2348. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Simpson EL: Dupilumab improves general
health-related quality-of-life in patients with moderate-to-severe
atopic dermatitis: Pooled results from two randomized, controlled
phase 3 clinical trials. Dermatol Ther (Heidelb). 7:243–248. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Blauvelt A, de Bruin-Weller M, Gooderham
M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC,
Rubel D, et al: Long-term management of moderate-to-severe atopic
dermatitis with dupilumab and concomitant topical corticosteroids
(LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded,
placebo-controlled, phase 3 trial. Lancet. 389:2287–2303. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Eichenfield L, Flohr C, Simpson E, DeBusk
K, Kin CY and Karl Y: Lebrikizumab improves patient-reported
outcomes (PROs) in a phase 2 study in patients with atopic
dermatitis. J Am Acad Dermatol. 76:AB423. 2017. View Article : Google Scholar
|
|
59
|
Hajar T, Gontijo JR and Hanifin JM: New
and developing therapies for atopic dermatitis. An Bras Dermatol.
93:104–107. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Snast I, Reiter O, Hodak E, Friedland R,
Mimouni D and Leshem YA: Are biologics efficacious in atopic
dermatitis? A systematic review and meta-analysis. Am J Clin
Dermatol. 19:145–165. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Neis MM, Peters B, Dreuw A, Wenzel J,
Bieber T, Mauch C, Krieg T, Stanzel S, Heinrich PC and Merk HF:
Enhanced expression levels of IL-31 correlate with IL-4 and IL-13
in atopic and allergic contact dermatitis. J Allergy Clin Immunol.
118:930–937. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Bilsborough J, Leung DY, Maurer M, Howell
M, Boguniewicz M, Yao L, Storey H, LeCiel C, Harder B and Gross JA:
IL-31 is associated with cutaneous lymphocyte antigen-positive skin
homing T cells in patients with atopic dermatitis. J Allergy Clin
Immunol. 117:418–425. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ruzicka T, Hanifin JM, Furue M, Pulka G,
Mlynarczyk I, Wollenberg A, Galus R, Etoh T, Mihara R, Yoshida H,
et al: XCIMA Study Group: Anti-interleukin-31 receptor A antibody
for atopic dermatitis. N Engl J Med. 376:826–835. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Leonardi CL, Kimball AB, Papp KA, Yeilding
N, Guzzo C, Wang Y, Li S, Dooley LT and Gordon KB: PHOENIX 1 study
investigators: Efficacy and safety of ustekinumab, a human
interleukin-12/23 monoclonal antibody, in patients with psoriasis:
76-week results from a randomised, double-blind, placebo-controlled
trial (PHOENIX 1). Lancet. 371:1665–1674. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Maeda S, Hayami Y, Naniwa T and Ueda R:
The Th17/IL-23 axis and natural immunity in psoriatic arthritis.
Int J Rheumatol. 2012:5396832012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Bromley SK, Larson RP, Ziegler SF and
Luster AD: IL-23 induces atopic dermatitis-like inflammation
instead of psoriasis-like inflammation in CCR2-deficient mice. PLoS
One. 8:e581962013. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Leonardi S, Cuppari C, Manti S, Filippelli
M, Parisi GF, Borgia F, Briuglia S, Cannavò P, Salpietro A, Arrigo
T, et al: Serum interleukin 17, interleukin 23, and interleukin 10
values in children with atopic eczema/dermatitis syndrome (AEDS):
Association with clinical severity and phenotype. Allergy Asthma
Proc. 36:74–81. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Agusti-Mejias A, Messeguer F, García R and
Febrer I: Severe refractory atopic dermatitis in an adolescent
patient successfully treated with ustekinumab. Ann Dermatol.
25:368–370. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Puya R, Alvarez-López M, Velez A, Casas
Asuncion E and Moreno JC: Treatment of severe refractory adult
atopic dermatitis with ustekinumab. Int J Dermatol. 51:115–116.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Fernández-Antón Martínez MC, Alfageme
Roldán F, Ciudad Blanco C and Suárez Fernández R: Ustekinumab in
the treatment of severe atopic dermatitis: A preliminary report of
our experience with 4 patients. Actas Dermosifiliogr. 105:312–313.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Shroff A and Guttman-Yassky E: Successful
use of ustekinumab therapy in refractory severe atopic dermatitis.
JAAD Case Rep. 1:25–26. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Samorano LP, Hanifin JM, Simpson EL and
Leshem YA: Inadequate response to ustekinumab in atopic dermatitis
- a report of two patients. J Eur Acad Dermatol Venereol.
30:522–523. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Wlodek C, Hewitt H and Kennedy CT: Use of
ustekinumab for severe refractory atopic dermatitis in a young
teenager. Clin Exp Dermatol. 41:625–627. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Noda S, Suárez-Fariñas M, Ungar B, Kim SJ,
de Guzman Strong C, Xu H, Peng X, Estrada YD, Nakajima S, Honda T,
et al: The Asian atopic dermatitis phenotype combines features of
atopic dermatitis and psoriasis with increased TH17 polarization. J
Allergy Clin Immunol. 136:1254–1264. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Dastidar SG, Rajagopal D and Ray A:
Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.
Curr Opin Investig Drugs. 8:364–372. 2007.PubMed/NCBI
|
|
76
|
Hanifin JM and Chan SC: Monocyte
phosphodiesterase abnormalities and dysregulation of lymphocyte
function in atopic dermatitis. J Invest Dermatol. 105 Suppl
1:84S–88S. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Souness JE, Aldous D and Sargent C:
Immunosuppressive and anti-inflammatory effects of cyclic AMP
phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology.
47:127–162. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Schafer PH, Parton A, Gandhi AK, Capone L,
Adams M, Wu L, Bartlett JB, Loveland MA, Gilhar A, Cheung YF, et
al: Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates
anti-inflammatory activity in vitro and in a model of psoriasis. Br
J Pharmacol. 159:842–855. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Samrao A, Berry TM, Goreshi R and Simpson
EL: A pilot study of an oral phosphodiesterase inhibitor
(apremilast) for atopic dermatitis in adults. Arch Dermatol.
148:890–897. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Abrouk M, Farahnik B, Zhu TH, Nakamura M,
Singh R, Lee K, Lucking SM, Blossom J, Liao W, Koo J, et al:
Apremilast treatment of atopic dermatitis and other chronic
eczematous dermatoses. J Am Acad Dermatol. 77:177–180. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Saporito RC and Cohen DJ: Apremilast use
for moderate-to-severe atopic dermatitis in pediatric patients.
Case Rep Dermatol. 8:179–184. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Oldhoff JM, Darsow U, Werfel T, Katzer K,
Wulf A, Laifaoui J, Hijnen DJ, Plötz S, Knol EF, Kapp A, et al:
Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab)
for the treatment of atopic dermatitis. Allergy. 60:693–696. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Oldhoff JM, Darsow U, Werfel T, Bihari IC,
Katzer K, Laifaoui J, Plötz S, Kapp A, Knol EF, Bruijnzeel-Koomen
CA, et al: No effect of anti-interleukin-5 therapy (mepolizumab) on
the atopy patch test in atopic dermatitis patients. Int Arch
Allergy Immunol. 141:290–294. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Buka RL, Resh B, Roberts B, Cunningham BB
and Friedlander S: Etanercept is minimally effective in 2 children
with atopic dermatitis. J Am Acad Dermatol. 53:358–359. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Jacobi A, Antoni C, Manger B, Schuler G
and Hertl M: Infliximab in the treatment of moderate to severe
atopic dermatitis. J Am Acad Dermatol. 52:522–526. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Boguniewicz M: Biologic therapy for atopic
dermatitis: Moving beyond the practice parameter and guidelines. J
Allergy Clin Immunol Pract. 5:1477–1487. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
McDonald BS, Jones J and Rustin M:
Rituximab as a treatment for severe atopic eczema: Failure to
improve in three consecutive patients. Clin Exp Dermatol. 41:45–47.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Roekevisch E, Spuls PI, Kuester D, Limpens
J and Schmitt J: Efficacy and safety of systemic treatments for
moderate-to-severe atopic dermatitis: A systematic review. J
Allergy Clin Immunol. 133:429–438. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Boguniewicz M, Jaffe HS, Izu A, Sullivan
MJ, York D, Geha RS and Leung DY: Recombinant gamma interferon in
treatment of patients with atopic dermatitis and elevated IgE
levels. Am J Med. 88:365–370. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Hanifin JM, Schneider LC, Leung DY, Ellis
CN, Jaffe HS, Izu AE, Bucalo LR, Hirabayashi SE, Tofte SJ,
Cantu-Gonzales G, et al: Recombinant interferon gamma therapy for
atopic dermatitis. J Am Acad Dermatol. 28:189–197. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Schneider LC, Baz Z, Zarcone C and
Zurakowski D: Long-term therapy with recombinant interferon-gamma
(rIFN-gamma) for atopic dermatitis. Ann Allergy Asthma Immunol.
80:263–268. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Stevens SR, Hanifin JM, Hamilton T, Tofte
SJ and Cooper KD: Long-term effectiveness and safety of recombinant
human interferon gamma therapy for atopic dermatitis despite
unchanged serum IgE levels. Arch Dermatol. 134:799–804. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Takiguchi R, Tofte S, Simpson B, Harper E,
Blauvelt A, Hanifin J and Simpson E: Efalizumab for severe atopic
dermatitis: A pilot study in adults. J Am Acad Dermatol.
56:222–227. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Moul DK, Routhouska SB, Robinson MR and
Korman NJ: Alefacept for moderate to severe atopic dermatitis: A
pilot study in adults. J Am Acad Dermatol. 58:984–989. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Werfel T, Breuer K, Ruéff F, Przybilla B,
Worm M, Grewe M, Ruzicka T, Brehler R, Wolf H, Schnitker J, et al:
Usefulness of specific immunotherapy in patients with atopic
dermatitis and allergic sensitization to house dust mites: A
multi-centre, randomized, dose-response study. Allergy. 61:202–205.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Bae JM, Choi YY, Park CO, Chung KY and Lee
KH: Efficacy of allergen-specific immunotherapy for atopic
dermatitis: A systematic review and meta-analysis of randomized
controlled trials. J Allergy Clin Immunol. 132:110–117. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Novak N, Bieber T, Hoffmann M,
Fölster-Holst R, Homey B, Werfel T, Sager A and Zuberbier T:
Efficacy and safety of subcutaneous allergen-specific immunotherapy
with depigmented polymerized mite extract in atopic dermatitis. J
Allergy Clin Immunol. 130:925–31.e4. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Gendelman SR and Lang DM: Specific
immunotherapy in the treatment of atopic dermatitis: A systematic
review using the GRADE system. Ann Allergy Asthma Immunol.
111:555–561. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Qin YE, Mao JR, Sang YC and Li WX:
Clinical efficacy and compliance of sublingual immunotherapy with
Dermatophagoides farinae drops in patients with atopic
dermatitis. Int J Dermatol. 53:650–655. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Pajno GB, Caminiti L, Vita D, Barberio G,
Salzano G, Lombardo F, Canonica GW and Passalacqua G: Sublingual
immunotherapy in mite-sensitized children with atopic dermatitis: A
randomized, double-blind, placebo-controlled study. J Allergy Clin
Immunol. 120:164–170. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Mastrandrea F, Serio G, Minelli M, Minardi
A, Scarcia G, Coradduzza G and Parmiani S: Specific sublingual
immunotherapy in atopic dermatitis. Results of a 6-year follow-up
of 35 consecutive patients. Allergol Immunopathol (Madr). 28:54–62.
2000.PubMed/NCBI
|
|
102
|
Darsow U: Allergen-specific immunotherapy
for atopic eczema: Updated. Curr Opin Allergy Clin Immunol.
12:665–669. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Bissonnette R, Papp KA, Poulin Y,
Gooderham M, Raman M, Mallbris L, Wang C, Purohit V, Mamolo C,
Papacharalambous J, et al: Topical tofacitinib for atopic
dermatitis: A phase IIa randomized trial. Br J Dermatol.
175:902–911. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Paller AS, Tom WL, Lebwohl MG, Blumenthal
RL, Boguniewicz M, Call RS, Eichenfield LF, Forsha DW, Rees WC,
Simpson EL, et al: Efficacy and safety of crisaborole ointment, a
novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the
topical treatment of atopic dermatitis (AD) in children and adults.
J Am Acad Dermatol. 75:494–503.e6. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Hanifin JM, Chan SC, Cheng JB, Tofte SJ,
Henderson WR Jr, Kirby DS and Weiner ES: Type 4 phosphodiesterase
inhibitors have clinical and in vitro anti-inflammatory effects in
atopic dermatitis. J Invest Dermatol. 107:51–56. 1996. View Article : Google Scholar : PubMed/NCBI
|
